Template:Oral hypoglycemics and insulin analogs: Difference between revisions
Content deleted Content added
WL |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 5: | Line 5: | ||
| listclass = hlist |
| listclass = hlist |
||
| group1 = [[Insulin]]s/[[insulin analog]]s |
| group1 = [[Insulin]]s / [[insulin analog]]s |
||
| list1 = {{Navbox|child |
| list1 = {{Navbox|child |
||
| Line 139: | Line 139: | ||
* [[Melogliptin]] |
* [[Melogliptin]] |
||
* [[Omarigliptin]] |
* [[Omarigliptin]] |
||
* [[Retagliptin]] |
|||
* [[Saxagliptin]] |
* [[Saxagliptin]] |
||
* [[Sitagliptin]] |
* [[Sitagliptin]] |
||
Latest revision as of 20:21, 3 January 2025
This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state= parameter may be used:
{{Oral hypoglycemics and insulin analogs|state=collapsed}}will show the template collapsed, i.e. hidden apart from its title bar.{{Oral hypoglycemics and insulin analogs|state=expanded}}will show the template expanded, i.e. fully visible.